| Methods |
Design:
randomized, placebo‐ controlled, double‐blind
parallel groups, 12 months |
| Participants |
Country: U.S.A., multi‐centre trial
n= 120 probable AD NINCDS/ADRDA, (97 completers), mild‐ moderate dementia (MMSE: 12‐28). Aged 56‐91. Hysterectomized, mix natural and surgical menopause. Exclusion criteria: age < 60, depression, CVD, types of medication (no use HRT last 3 months, stabile use donazepil allowed). |
| Interventions |
1. CEE oral 0.625 mg/day
2. CEE 1.25 oral mg/day
2. Placebo |
| Outcomes |
General (MMSE, ADAS‐Cog)
Memory (new dot test, face recognition)
Speed: (TMT, letter cancellation, finger tapping, DSST) Language (Fluency) |
| Notes |
HRT> placebo MMSE after 2 months, after 12 month worse
(Fluency, finger tapping) 1/9 tests
Adverse events: 4 had deep vein thrombosis, 2 vaginal bleeding |
